The Prostate Cancer Prevention Trial (PCPT) of finasterideresulted in reduced cancers among the intervention group; however, among the men diagnosed with prostate cancer, the absolute number of tumors with high Gleason score was greater in the finasteride arm than in the placebo arm. Many of the known and suspected risk factors for prostate cancer are associated with higher levels of reactive oxygen species (ROS) or decreased antioxidant capabilities. Oxidative stress results from an imbalance between ROS and antioxidant capacities, which can cause direct DNA damage and mutations. There are extensive DNA repair systems that can correct damaged DNA before cell replication and mutation fixation, although inherent variability can result in diminished DNA repair capabilities. Additional data presented in this revised application on DNA repair and oxidative stress in prostate cancer further strengthen the hypothesis that these two pathways are involved in risk. Using biospecimens and data collected in PCPT and in the other projects of this P01, we intend to: 1) evaluate potential risk factors for prostate cancer that are linked to an oxidative stress/DNA repair mechanism; and 2) investigate mechanisms whereby finasteride could be associated with high grade tumors. We will determine whether polymorphisms in genes encoding enzymes that generate ROS, neutralize ROS, and repair DNA damage are associated with risk of prostate cancer and high grade cancer. We will also measure serum levels of oxidized proteins, a biomarker of oxidative damage, to determine if baseline levels of oxidative stress are elevated in those who go on to develop cancer and whether finasteride influences its level. In cross-project interactive aims, we will collaborate with investigators in other projects in this P01 to better understand the role of oxidative stress and DNA repair in prostate cancer risk. With Project 2, we will determine whether associations of dietary factors with prostate cancer differ by oxidative stress genotype and with Project 4 whether genotype for oxidative stress and DNA repair genes are associated with prevalence and extent of atrophy and inflammation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108964-02
Application #
7311253
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2006
Total Cost
$203,851
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Tang, Li; Platek, Mary E; Yao, Song et al. (2018) Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39:125-133
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Miles, Fayth L; Goodman, Phyllis J; Tangen, Catherine et al. (2017) Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9:
Chen, Haitao; Liu, Xu; Brendler, Charles B et al. (2016) Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate 76:1120-9
Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
(2016) Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 9:116-7
Patel, Darshan P; Schenk, Jeannette M; Darke, Amy et al. (2016) Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial. BJU Int 117:500-6
Travis, Ruth C; Appleby, Paul N; Martin, Richard M et al. (2016) A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Res 76:2288-2300
Winchester, Danyelle A; Gurel, Bora; Till, Cathee et al. (2016) Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate 76:565-74

Showing the most recent 10 out of 71 publications